189 related articles for article (PubMed ID: 37979099)
1. The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer.
Bimonte VM; Catanzaro G; Po A; Trocchianesi S; Besharat ZM; Spinello Z; Curreli M; Fabi A; Bei R; Milella M; Vacca A; Ferretti E; Migliaccio S
Endocrine; 2024 Mar; 83(3):798-809. PubMed ID: 37979099
[TBL] [Abstract][Full Text] [Related]
2. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
3. Cadmium exposure alters steroid receptors and proinflammatory cytokine levels in endothelial cells in vitro: a potential mechanism of endocrine disruptor atherogenic effect.
Fittipaldi S; Bimonte VM; Soricelli A; Aversa A; Lenzi A; Greco EA; Migliaccio S
J Endocrinol Invest; 2019 Jun; 42(6):727-739. PubMed ID: 30478740
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.
Hamel KM; King CT; Cavalier MB; Liimatta KQ; Rozanski GL; King TA; Lam M; Bingham GC; Byrne CE; Xing D; Collins-Burow BM; Burow ME; Belgodere JA; Bratton MR; Bunnell BA; Martin EC
Stem Cells Dev; 2022 Oct; 31(19-20):604-620. PubMed ID: 35579936
[TBL] [Abstract][Full Text] [Related]
5. New aspects of cadmium as endocrine disruptor.
Takiguchi M; Yoshihara S
Environ Sci; 2006; 13(2):107-16. PubMed ID: 16788562
[TBL] [Abstract][Full Text] [Related]
6. Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
Kikuchi K; McNamara KM; Miki Y; Moon JY; Choi MH; Omata F; Sakurai M; Onodera Y; Rai Y; Ohi Y; Sagara Y; Miyashita M; Ishida T; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Dec; 166(3):709-723. PubMed ID: 28831645
[TBL] [Abstract][Full Text] [Related]
7. The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells.
Yu X; Filardo EJ; Shaikh ZA
Toxicol Appl Pharmacol; 2010 May; 245(1):83-90. PubMed ID: 20153348
[TBL] [Abstract][Full Text] [Related]
8. The endocrine disruptor cadmium alters human osteoblast-like Saos-2 cells homeostasis in vitro by alteration of Wnt/β-catenin pathway and activation of caspases.
Papa V; Bimonte VM; Wannenes F; D'Abusco AS; Fittipaldi S; Scandurra R; Politi L; Crescioli C; Lenzi A; Di Luigi L; Migliaccio S
J Endocrinol Invest; 2015 Dec; 38(12):1345-56. PubMed ID: 26335301
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer.
Liu WJ; Zhao G; Zhang CY; Yang CQ; Zeng XB; Li J; Zhu K; Zhao SQ; Lu HM; Yin DC; Lin SX
J Cell Biochem; 2020 Apr; 121(4):2756-2769. PubMed ID: 31693255
[TBL] [Abstract][Full Text] [Related]
10. Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Gingras S; Moriggl R; Groner B; Simard J
Mol Endocrinol; 1999 Jan; 13(1):66-81. PubMed ID: 9892013
[TBL] [Abstract][Full Text] [Related]
11. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathway.
Ali I; Penttinen-Damdimopoulou PE; Mäkelä SI; Berglund M; Stenius U; Akesson A; Håkansson H; Halldin K
Environ Health Perspect; 2010 Oct; 118(10):1389-94. PubMed ID: 20525538
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Androst-5-ene-3β,17β-diol and 5α-androstane-3β,17β-diol with estrogen and androgen receptors: a combined binding and cell study.
Chen J; Wang WQ; Lin SX
J Steroid Biochem Mol Biol; 2013 Sep; 137():316-21. PubMed ID: 23416106
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
15. [Dual effects of androgens on mammary gland].
Brettes JP; Mathelin C
Bull Cancer; 2008 May; 95(5):495-502. PubMed ID: 18541513
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
[TBL] [Abstract][Full Text] [Related]
17. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
18. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
Basile D; Cinausero M; Iacono D; Pelizzari G; Bonotto M; Vitale MG; Gerratana L; Puglisi F
Cancer Treat Rev; 2017 Dec; 61():15-22. PubMed ID: 29078133
[TBL] [Abstract][Full Text] [Related]
20. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
Suba Z
Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
